A new experimental drug has the potential to change the way advanced breast cancer is treated. It blocks the progression of ER positive breast cancer, which makes up about 60% of breast cancers, by targeting molecules involved in cell division. Patients who took the drug during trials doubled the amount of time they lived without the cancer getting worse — extending this time, on average, by 10 months. Because of the unique nature of the drug, it could also have an impact on other cancers as well, such as pancreatic and lung cancers.
CBS This Morning speaks with Dr. David Agus about this new drug, and when it could potentially be approved by the FDA. Take a look.Whizzco